ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OMER / earnings
NKTR (20) DMRA (35) KARD (46) AAPG (45) ⌘ Pro Terminal →

Omeros Corporation (OMER) Next Earnings Date & Expected ±10.7% Move

$17.83 -3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.69

Omeros Corporation (OMER) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OMER Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OMER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Omeros Corporation (NASDAQ: OMER) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $17.83 (-3.31% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OMER ranks #436 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OMER compare to NKTR and DMRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OMER carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and DMRA (Damora Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, OMER leads on earnings multiple (N/A) while OMER leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OMER?
▼

Per OMER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285819), Omeros Corporation generated $343.8M in revenue (-26.4% YoY), $0 in net income, and -$116.2M in free cash flow against $325.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $17.69 (-0.79%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D+
Cash (6)Whales (11)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
$22 Bull$16 Base$13 Bear
📬 FREE OMER RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OMER)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY OMER SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±10.7% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)

FRED Regime × Technicals: 77% of 52W Range • RSI-14 at 52.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$18.88-12.3% Next Q
Q2 (-2Q)
46
Grade D$16.55+5.7% Next Q
Q3 (-1Q)
44
Grade D$17.49+1.9% Next Q
Current
41
Grade D-$17.83-7.2% Hist 90D α
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OMER Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OMER currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.50) and Max Pain ($18.72) forces dealer call-delta covering toward $22.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OMER• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OMER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±10.7% Swing Band

±$1.91 Expected Swing
$15.92 (-10.7%)Spot $17.83$19.74 (+10.7%)
MODEL EARNINGS SETUP GAUGE

OMER Quantitative Pre-Earnings Setup: 41/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (41/100)Model Risk Weight (59/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$343.8M$0-$116.2M52%
FY 20242024-12-31$467.5M$0-$149.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMER)

  • ✓Walkthrough of OMER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OMER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.58%🛡️ HOLDING TREND SUPPORT
2026-11-03O $18.95H $18.95L $17.83C $17.83VOL 885.6K
RES: $20.53SUP: $17.11SMA50: $18.50SMA200: $13.55
$22.26$18.04$13.82$9.61$5.39RES $20.53SUP $17.11$17.832026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OMER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OMER Butterfly Map → + Track OMER →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -26.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OMER today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OMER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OMER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMER)

Health Care Rank #436 of 1015 ⚔️ NKTR vs OMER Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OMER vs. NKTR, DMRA, KARD, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Omeros Corporation (OMER) ranks #436 by composite RQD confidence (41/100, grade D-) and #315 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, OMER leads on earnings valuation at N/A trailing P/E, while OMER leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with OMER at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OMER ACTIVE
Omeros Corporation
D- 41/100 — — -35.0% -3.31% $1.33B Benchmark Subject
NKTR
Nektar Therapeutics
E 20/100 — 96.0% -35.0% -4.94% $1.33B /nktr-vs-omer →
DMRA
Damora Therapeutics Inc.
D- 35/100 — — -35.0% +0.51% $1.33B /dmra-vs-omer →
KARD
Kardigan Inc.
D 46/100 — — — +0.57% $1.32B /kard-vs-omer →
AAPG
Ascentage Pharma Group International American Depository Shares
D 45/100 — — — -6.20% $1.35B /aapg-vs-omer →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285819 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omeros Corporation (OMER) reported GAAP revenue of $343.8M (-26.4% vs. FY2024 revenue of $467.5M ) , GAAP net income of $0, operating cash flow of -$116.1M, and free cash flow of -$116.2M (+22.0% YoY). On the balance sheet, OMER closed FY2025 with $325.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $343.8M $0 -$116.1M -$116.2M $325.6M —
FY2024 (FY) 2024-12-31 $467.5M $0 -$148.8M -$149.0M $277.1M —

3. OMER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OMER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Omeros Corporation (NASDAQ: OMER) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $17.83 (-3.31% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OMER ranks #436 in composite RQD confidence.

How does OMER compare to NKTR and DMRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OMER carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and DMRA (Damora Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, OMER leads on earnings multiple (N/A) while OMER leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OMER?

Per OMER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285819), Omeros Corporation generated $343.8M in revenue (-26.4% YoY), $0 in net income, and -$116.2M in free cash flow against $325.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OMER trading relative to its 50-day, 200-day, and 52-week technical levels?

OMER last traded at $17.83 (-3.31% on volume of 903,526 shares), positioning the stock -3.62% below its 50-day simple moving average ($18.50) and +31.59% above its 200-day simple moving average ($13.55). Across its 52-week range of $6.24 to $21.24, OMER sits at the 77.3% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($15.92 to $19.74).

Direct Sub-Reports: OMER RQD Cockpit OMER 12M Forecast OMER Earnings & Move OMER Dividends & DRIP OMER Insiders & 13F OMER Whale Options OMER Profit Sankey OMER News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

OMER — Omeros Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Omeros Corporation (OMER) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $17.83 (-3.31% 1D, market capitalization $1.33B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -8.47%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Omeros Corporation (OMER) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry..4B. Revenue is reported as — in the SEC financials for both FY 2025 and FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Omeros Corporation (OMER) reported $343.8M in annual revenue (up from $467.5M in FY2024, -26.4% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2024 ($467.5M revenue, $0 net income) through FY2025, OMER scaled operating cash flow to -$116.1M and free cash flow to -$116.2M, backed by $325.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.47% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $6.24 – $21.24 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— supply_chain is NONE, butterfly_links is empty, and no proprietary signals are present. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be established from the source data.

  • Key Question #1: Can OMER sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $343.8M and free cash flow of -$116.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is OMER's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OMER Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Omeros Corporation (OMER) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OMER Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OMER Bull vs. Bear Conversation Board — What's Your Call at $17.83?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OMER 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OMER:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $21.94 (+19.0%)
📌 Pinned Debate

Whale 13F Flow scores 16 of 20, the strongest RQD pillar, showing institutional accumulation and options positioning despite weak funda

Don't sleep on OMER's setup in Health Care. Whale 13F Flow scores 16 of 20, the strongest RQD pillar, showing institutional accumulation and options positioning despite weak fundamentals.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (41/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@RedlineAuditor Shorting a 11/20 institutional whale-flow stock at $18.44 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $13.83 (-25.0%)
Spot @ $18.44

ROIC of -35% and FCF yield of -8.47% alongside Piotroski F 1/9 show a company consuming cash with weak financial quality.

Sitting on the sidelines or leaning short OMER above $18.44. ROIC of -35% and FCF yield of -8.47% alongside Piotroski F 1/9 show a company consuming cash with weak financial quality.. Until Fundamental Cash Engine (6/20) and FCF yield (-8.47%) inflect higher, upside is capped near $21.24.

LIVE TAPE